CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies
Metrics: PDF 156 views | Full Text 1047 views | ?
Daniel Morillo1, Gala Vega1 and Victor Moreno2
1 Division of Hematology, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain
2 Division of Oncology, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain
|Victor Moreno,||email:||[email protected]|
Keywords: cyclin-dependent kinases (CDK); CDK9; hematological malignancies
Received: April 18, 2023 Accepted: June 21, 2023 Published: August 07, 2023
Most hematological malignancies are characterized by overexpression of certain cancer promoting genes, such as MYC, MCL1 and cyclin D1. Preclinical studies in animal models have shown that CDK9 inhibitors supress the transcription of these anti-apoptotic and pro-survival proteins, and suggest their potential synergism with other drugs. In its first in-human trial, enitociclib demonstrated clinical activity in a small cohort of patients with high grade B lymphoma with MYC and BCL2 and/or BCL6 rearrangements, inducing complete responses in 2 of 7 subjects (29%) in monotherapy. These data suggest CDK9 inhibitors could play a role in the treatment of hematological diseases and could be a great ally when combined with other therapeutic approaches.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.